An accident which saw a woman trip and fall outside a hospital led to her death, a coroner has found. Lorna Loxton, a former ...

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...

Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the ...

Lorna Loxton, 55, had been attending a cardiology appointment at Bristol Royal Infirmary when she fell over a protruding ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...

An analysis of genetic data from over 900,000 people shows that certain stretches of DNA, made up of short sequences repeated ...

LoQus23 Therapeutics Ltd ("LoQus23"), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington's Disease ...

As of Thursday, January 08, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.03%, which has investors questioning if ...

A large genetic study shows that many people carry DNA sequences that slowly expand as they get older. Common genetic ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...